Cystatin C: Drugs That Distort This Kidney Test and How to Read Your Results

What Cystatin C Measures and Why It's Ordered

Cystatin C is a small cysteine protease inhibitor produced at a fairly steady rate by nearly every nucleated cell in the body. The kidneys filter it freely at the glomerulus and then reabsorb and break it down in the proximal tubule, so blood levels rise as filtration falls. That makes it a window into glomerular filtration rate (GFR) that doesn't depend on muscle mass the way creatinine does.

The 2012 KDIGO guideline recommends using cystatin C as a confirmatory test when creatinine-based eGFR falls near a diagnostic threshold, particularly around the 60 mL/min/1.73 m² cutoff that helps define stage 3 chronic kidney disease [1]. A large pooled analysis published in the New England Journal of Medicine found that adding cystatin C to creatinine improved how accurately clinicians could classify risk for death, cardiovascular events, and kidney failure compared with creatinine alone [2]; the exact proportion of patients reclassified varies by population and should be checked against the primary paper rather than quoted as a single fixed number.

Creatinine depends heavily on skeletal muscle mass, which creates blind spots in older adults with reduced muscle mass, people on low-protein or vegetarian diets, and people with limb amputations. Cystatin C is not meaningfully driven by age, sex, or ethnicity at the level of production, which is part of why the 2021 CKD-EPI equation that incorporates cystatin C was able to drop the race coefficient entirely [3].

Normal Range and How to Read a Result

A normal serum cystatin C in a healthy adult generally falls between about 0.56 and 0.98 mg/L, though the exact reference interval depends on the laboratory and assay used. Values above roughly 1.0 mg/L typically point toward reduced filtration, but "typically" matters here: the number should always be read alongside the lab's own reference range and, ideally, the same assay used for any prior result.

The relationship is inverse: as kidney function declines, cystatin C rises. For illustration, a level of 1.25 mg/L in a 55-year-old without any of the confounders described below could correspond to an eGFR in the CKD stage 3a range, but this is an approximation for context, not a substitute for a formal eGFR calculation done by a clinician [1]. Cystatin C tends to be more sensitive than creatinine in the "creatinine-blind range" (eGFR roughly 60 to 90 mL/min/1.73 m²), where creatinine can look normal even as early kidney damage develops.

The International Federation of Clinical Chemistry certified a reference material to help standardize cystatin C assays across manufacturers [4]. Before that standardization effort, results for the same blood sample could differ meaningfully depending on which assay a lab used. Standardization has narrowed that gap, but it's still worth confirming which assay a lab uses before comparing serial results drawn at different facilities.

Children have different reference ranges than adults. Cystatin C tends to run higher in newborns, partly reflecting maternal levels, and settles toward adult ranges over the first year of life [5].

Drugs That Can Falsely Raise Cystatin C

Several medications increase serum cystatin C through mechanisms unrelated to kidney filtration. Recognizing these matters because mistaking a drug effect for kidney decline can lead to an incorrect CKD diagnosis or unnecessary anxiety.

Corticosteroids are the best-documented and most clinically important confounder. Studies in transplant and pediatric oncology patients have found that systemic corticosteroids such as prednisone, dexamethasone, and methylprednisolone can raise cystatin C without a corresponding change in true GFR measured by reference methods like inulin clearance [6, 7]. The proposed mechanism involves glucocorticoid response elements in the cystatin C gene promoter (CST3), which may directly increase how much cystatin C cells produce. The magnitude of the effect varies by dose, drug, and study population; treat reported percentage ranges as approximate rather than a precise dosing table, and rely on trends over time rather than a single cutoff.

Cyclosporine poses a dual problem. It causes genuine nephrotoxicity, but there's also evidence it independently affects cystatin C production separate from its effect on the kidney itself. Separating the drug's direct effect on the biomarker from its effect on the kidney usually requires serial monitoring and, in ambiguous cases, a more direct GFR measurement [8].

High-dose methotrexate used in oncology has been associated with early cystatin C changes that may reflect genuine early tubular injury rather than a pure assay artifact, so a rising cystatin C during methotrexate therapy should generally be treated as a real signal worth investigating, not dismissed as a drug interference effect [9].

The practical takeaway: if a patient is on systemic corticosteroids and their cystatin C-based eGFR looks meaningfully worse than their creatinine-based eGFR, that gap may be pharmacologic rather than renal. Levey, Inker, and Coresh, whose work underlies the current CKD-EPI equations, have written elsewhere that cystatin C should be interpreted with the same caution clinicians already apply to creatinine, because no single biomarker is free of influences unrelated to GFR [10].

Drugs and Conditions That Can Falsely Lower Cystatin C

Fewer medications suppress cystatin C, but a falsely low result is arguably more dangerous, because it can mask real kidney disease.

Thyroid status is the best-documented factor here. Hyperthyroidism, whether from the thyroid gland itself or from over-replacement with levothyroxine, has been associated with lower cystatin C levels in cross-sectional studies [11]. The proposed mechanism is thyroid hormone-related suppression of cystatin C gene expression. People adjusting their levothyroxine dose after thyroidectomy are particularly worth watching during periods when TSH runs below target, since a temporarily suppressed TSH could correspond to an artificially reassuring cystatin C.

The mirror-image problem is also real: untreated or undertreated hypothyroidism tends to raise cystatin C independent of actual GFR [11]. A patient with a markedly elevated TSH could show an elevated cystatin C that normalizes once thyroid hormone levels are corrected. Without recognizing the thyroid connection, a clinician could diagnose CKD that was never actually present.

mTOR inhibitors such as everolimus and sirolimus have shown inconsistent effects on cystatin C in transplant literature, with some studies reporting modest suppression at therapeutic levels [12]. The evidence isn't consistent enough to support a blanket rule, so transplant teams generally cross-check with a direct clearance measurement like iothalamate or iohexol when interpreting cystatin C around changes in mTOR inhibitor dosing.

Reading a Cystatin C Result: A Decision Framework

Because so many non-kidney factors can move this number, a single cystatin C value in isolation is rarely enough to act on. This framework walks through the questions worth asking before treating a cystatin C result as a reliable statement about kidney function.

Step 1: Screen for the biggest confounders first.

• Is the patient currently on a systemic corticosteroid (oral, IV, or high-dose inhaled)? If yes, expect cystatin C to potentially overstate kidney impairment, and weight creatinine-based or combined equations more heavily.
• What is the most recent TSH, ideally within the last three months? Untreated hyperthyroidism or recent over-replacement of thyroid hormone can make cystatin C look falsely reassuring; untreated hypothyroidism can make it look falsely alarming.
• Is the patient on cyclosporine, tacrolimus, or an mTOR inhibitor? Both true nephrotoxicity and direct biomarker interference can be present at once, which is why serial trends matter more than a single number.

Step 2: Weigh the smaller, additive factors.

• A BMI above 30 has been associated with modestly higher cystatin C independent of measured GFR in some cohort studies [14].
• Active systemic inflammation (for example, a CRP well above normal during a lupus or rheumatoid arthritis flare) has been linked to a small upward shift in cystatin C [15].
• Current smoking has been associated with a modest independent increase in some studies [14].
• Certain cancers, particularly with high proliferative activity, have been linked to elevated cystatin C through mechanisms unrelated to kidney filtration [16].

None of these factors alone should change a CKD diagnosis. They matter most when several are present together, or when they help explain an otherwise puzzling discrepancy.

Step 3: Compare the two eGFR equations. Look at creatinine-based eGFR next to cystatin C-based eGFR. If they diverge by more than roughly 20 to 30 percent, treat that gap as a prompt to look for one of the confounders above before changing a CKD stage assignment, rather than assuming the lower of the two numbers is automatically correct.

Step 4: Know the exception that overrides this framework. If the clinical stakes are high enough, such as transplant listing, chemotherapy dosing near a toxicity threshold, or contrast administration in someone with borderline kidney function, don't try to reason through confounders at all. Ask for a directly measured GFR using iohexol or iothalamate clearance. That test sidesteps the entire discussion above and is the appropriate next step when an estimate isn't precise enough for the decision at hand [1].

Step 5: When in doubt, trend, don't single-point. A cystatin C drawn while starting a pulse steroid course, during a thyroid dose adjustment, or during an inflammatory flare tells you less than the same test repeated after the confounder resolves. If a result doesn't match the clinical picture, the most useful next step is often to repeat the test after the suspected confounder has passed rather than to act on the single value.

Corticosteroids Deserve Extra Attention

Long-term oral glucocorticoid use is common enough that it's worth a dedicated look. A UK population study found that roughly 1 percent of adults were on a long-term oral glucocorticoid prescription at any given time [13]; use patterns in other countries, including the US, are plausibly similar in order of magnitude but haven't been independently confirmed here, so treat that figure as a rough sense of scale rather than a precise US statistic.

Anyone on chronic prednisone for rheumatoid arthritis, inflammatory bowel disease, or transplant maintenance is carrying a cystatin C confounder that doesn't affect creatinine in the same way. Reported effect sizes vary by dose, drug, and study population, and pulse-dose steroids (very high, short courses) appear to have a larger and faster effect than low daily maintenance doses, with levels drifting back toward baseline over the days after a pulse ends [6, 7]. Rather than relying on a fixed percentage-per-dose table, the more reliable approach is: for patients on any systemic corticosteroid, don't use cystatin C alone to stage CKD, and use the combined creatinine-cystatin C equation instead of either marker in isolation. The 2012 KDIGO guideline explicitly lists corticosteroid use, thyroid dysfunction, obesity, inflammation, malignancy, and smoking as non-GFR factors that should be weighed when interpreting a cystatin C result [1].

When Cystatin C Is Actually Worth Ordering

Not every patient needs a cystatin C test. It costs more than creatinine, and in a healthy adult with typical muscle mass and no confounders, creatinine-based eGFR is usually adequate on its own.

KDIGO guidance points to specific scenarios where cystatin C, alone or combined with creatinine, adds real value [1]:

• Confirming CKD when creatinine-based eGFR sits in a borderline range (roughly 45 to 59 mL/min/1.73 m²) and no other marker of kidney damage, such as albuminuria or a structural abnormality, is present
• Patients at the extremes of muscle mass: bodybuilders, people with amputations, and those with advanced muscle wasting or neuromuscular disease
• Patients on drugs known to interfere with creatinine itself, such as trimethoprim, cimetidine, or cobicistat, which block tubular creatinine secretion and can falsely raise serum creatinine without any real change in GFR
• Living kidney donor evaluation, where an accurate GFR estimate has lasting consequences for the donor

A large cohort study of patients with established CKD found that a combined creatinine-cystatin C equation predicted kidney failure somewhat more accurately than either marker alone [17]; the exact discrimination statistics reported in that paper should be checked directly before quoting a specific number, but the direction of the finding, that combining both markers modestly outperforms either alone, is consistent with the broader literature. The developers of the 2021 race-free CKD-EPI equations describe the combined equation as offering a favorable balance of accuracy and equity, since removing the race coefficient did not come at the cost of precision across the GFR range [3].

Addressing an Elevated Cystatin C: What Actually Helps

"How to lower cystatin C" is an understandable search, but it's worth reframing. Cystatin C is a marker, not a disease in itself. Artificially lowering it, for instance by inducing mild hyperthyroidism, would hide a kidney problem rather than treat it.

The genuine path to a lower cystatin C is either improving actual kidney function or resolving whichever non-renal confounder pushed the number up. Reasonable, evidence-supported steps include:

Blood pressure control. The SPRINT trial, a large randomized trial in high-risk adults without diabetes, found that targeting a systolic blood pressure below 120 mmHg reduced cardiovascular events and death compared with a target below 140 mmHg [18, SPRINT primary results]. Its effects on kidney-specific outcomes differed between people who already had CKD at baseline and those who didn't, so "lower blood pressure reduces kidney risk" is broadly true but shouldn't be reduced to a single percentage without checking which subgroup that number applies to. In general, better-controlled blood pressure means less glomerular strain over time, which supports stable or improving cystatin C.

SGLT2 inhibitors. In the DAPA-CKD trial, dapagliflozin reduced the risk of the trial's composite kidney outcome (sustained eGFR decline, kidney failure, or kidney/cardiovascular death) by about 39 percent in patients with CKD, regardless of whether they had diabetes [19, DAPA-CKD trial results]. These drugs are now a standard part of CKD management for appropriate patients, and people who respond tend to see eGFR, and by extension cystatin C, stabilize.

Stopping nephrotoxic drugs when possible. NSAIDs, aminoglycoside antibiotics, and high-dose lithium can cause dose-dependent kidney injury. Stopping the offending agent, where clinically appropriate and under medical guidance, allows GFR to recover and cystatin C to decline correspondingly.

Treating the actual confounder. If cystatin C is elevated because of a corticosteroid, the value should trend down as the steroid is tapered. If untreated hypothyroidism is the driver, levothyroxine replacement should correct the artifact over the following weeks as TSH normalizes.

There's no supplement, food, or lifestyle intervention with controlled-trial evidence for selectively lowering cystatin C production. Claims about "cystatin C-lowering" diets or supplements aren't supported by the evidence reviewed for this article.

Questions People Ask

If a cystatin C result doesn't match how you feel or what your other labs show, that's worth a direct conversation with the clinician who ordered it rather than something to interpret alone.